Both existing and potential investors of Kraig Biocraft Laboratories Inc (KBLB.OB) should understand that they have one of the most pioneering and accomplished minds in the field of genetic engineering working in their corner. This member of Kraig’s Scientific Advisory Board, Dr. Malcolm Fraser, presides over the University of Notre Dame’s transgenic-based laboratory which has currently been focusing on developing “spider silk” polymers.
Since Kraig and Notre Dame have partnered in a collaboration agreement, essentially exchanging funding for both R&D data and intellectual property rights, Kraig is uniquely positioned to benefit from the work conducted under Dr. Fraser at Notre Dame. Consequently, the company’s stock performance will be heavily tied to Dr. Fraser’s breakthroughs in the laboratory.
Considering Kraig’s track record, investors should feel at ease with the notion that his work can single handedly affect Kraig’s stock price. Shortly after the turn of the century, Dr. Fraser patented what has become one of the most utilized methods directed to insert genes in insects. Since this US Patent 6,218,185 titled Piggybac transposon-based genetic transformation system for insects was issued, over 190 pending or patented applications have come through the United States Patent and Trademark Office.
A recent study also compared this Piggybac transposon to three other transposons commonly used for “jumping genes” into insects, and subsequently found the Piggybac transposon performed five to ten times better. As a result of this technical breakthrough pioneered by Dr. Fraser, universities across the globe have already paid over $300,000 to his group in licensing fees in order to use this Piggybac metholodology in their laboratories.
Now that Kraig has joined forces with Dr. Fraser, research and development has focused on incorporating this Piggybac technique in silkworms such that high performance spider silk polymers can be spun. The rapid progress in this area of spider silk has already been highlighted by the filing of at least two provisional patent applications under the assignee of the University of Notre Dame. While these applications have not been made public and have yet to be examined, this is a very welcoming sign of good things to come under the direction of Dr. Fraser and Kraig Biocraft Laboratories Inc.
Let us hear your thoughts: Kraig Biocraft Laboratories, Inc. Message Board
